APP and metabolic dysfunction-associated steatohepatitis: In liver samples from patients with MASH, we found reduced Aβ-42 concentrations, which were not dependent on the expression of APP or Aβ transport proteins, but most likely caused by (i) an increased degradation of APP towards the non-amyloidogenic pathway, (ii) a degraded generation of Aβ peptides along the amyloidogenic pathway, and (iii) an enhanced expression of genes removing Aβ-42.